Neoplasms

All Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Ear, Nose, and Throat Diseases

Mouth and Tooth Diseases

Rare Diseases

Carcinoma

Laryngeal Diseases

Hypopharyngeal Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Pharyngeal Neoplasms

Otorhinolaryngologic Neoplasms

Head and Neck Neoplasms

Pharyngeal Diseases

Stomatognathic Diseases

Otorhinolaryngologic Diseases

Hypopharyngeal Cancer

Antineoplastic Agents

All Drugs and Chemicals

Paclitaxel

Fluorouracil

Albumin-Bound Paclitaxel

Cisplatin

Patients receive 2 cycles of paclitaxel, cisplatin and 5-Fluorouracil chemotherapy followed by Surgery or Chemo-radiotherapy according to the response status after induction chemo.

Patients receive single-agent cisplatin chemotherapy concurrent with Radiotherapy

Induction CT: Paclitaxel 175mg/m2 IV on d1 and d22, cisplatin 75mg/m2 IV on d1 and d22, 5-Fluorouracil 750mg/m2 IV continuously on d1-4 and d22-25, CRT: cisplatin 80mg/m2 IV on d1 of each 21 days cycle and 70 Gy radiotherapy

Induction CT+ CRT group

cisplatin 100mg/m2 IV on d1 of each 21 days cycle and 70 Gy radiotherapy

Concurrent CRT group

Junlin Yi, Professor

Junlin YI, MD

To develope stratification treatment for the patients who have locally advanced hypopharyngeal carcinoma. Experimental group patients were treated individually according to the response status after induction chemotherapy, receiving chemoradiotherapy or surgery. Thus to achieve a better survival rate and a higher larynx-preservation rate as well as a lower treatment related toxicity rate compared with standard treatment.

Eligiblity patient were assign to induction chemotherapy plus concurrent chemotherapy group (IC +CCRT group, Arm A)and concurrent chemoradiotherapy group(CCRT group, Arm B). For patients in Arm A, treatment response were evaluated after 2cycles, if the response reached partial response/complete response, patients received concurrent chemoradiotherapy, otherwise, patients will received surgery and radiotherpay/concurrent chemoradiotherapy after surgery. For patients received concurrent chemoradiotherapy (both in Arm A and Arm B) , treatment response were evaluated at 50 Gy. if response reached complete response or major partial response(\>80% tumor regression), patients will received radical chemoradiotherapy, otherwise, patients will received surgery.

New Strategy of Improving Treatment Outcome and Larynx-preservation Rate in Locally Advanced Hypopharyngeal Carcinoma

hematology and surgery related complications

Chinese Academy of Medical Sciences

Professor

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
New Strategy of Improving Treatment Outcome and Larynx-preservation Rate in Locally Advanced Hypopharyngeal Carcinoma	NCT03558035	Hypopharyngeal ...	Induction CT+ C... Concurrent CRT ...	18 Years - 70 Years	ChineseAMS
New Strategy of Improving Treatment Outcome and Larynx-preservation Rate in Locally Advanced Hypopharyngeal Carcinoma	NCT03558035	Hypopharyngeal ...	Induction CT+ C... Concurrent CRT ...	18 Years - 70 Years	ChineseAMS
New Strategy of Improving Treatment Outcome and Larynx-preservation Rate in Locally Advanced Hypopharyngeal Carcinoma	NCT03558035	Hypopharyngeal ...	Induction CT+ C... Concurrent CRT ...	18 Years - 70 Years	ChineseAMS

Spots Global Cancer Trial Database for concurrent crt group